Views: 0 Author: Site Editor Publish Time: 2026-01-23 Origin: Site
As we move through 2026, the global fight against multi-drug resistant pathogens like MRSA and VRE relies heavily on the antibiotic Linezolid. However, the therapeutic efficacy of Linezolid is strictly dependent on its (S)-enantiomer. The (5R)-isomer—CAS 168828-82-8—is a process-related impurity that must be rigorously monitored.
This compound, also known as PNU-100440, is the primary hydroxymethyl byproduct formed during the synthesis of Linezolid. For 2026 pharmaceutical manufacturers, having a high-purity reference of this impurity is not just a regulatory requirement; it is a fundamental part of patient safety protocols.
This molecule is a chiral oxazolidinone derivative. Structurally, it consists of a central 2-oxazolidinone ring with a (5R)-hydroxymethyl group, substituted at the 3-position with a 3-fluoro-4-morpholinophenyl moiety. It is the "enantiomeric mirror" or "hydroxylated precursor" to the active antibiotic, making its identification during HPLC analysis critical.
In the current 2026 industrial landscape, its applications are specialized:
Used to calibrate HPLC and LC-MS instruments to detect and quantify process-related impurities in Linezolid batches.
Employed to verify the efficiency of chiral stationary phases in separating (R) and (S) isomers.
Used in pharmacological research to study the degradation pathways of oxazolidinone antibiotics in biological systems.
Using an ultra-pure standard (>99.0%) from a trusted source like EASTFINE provides:
Meets the strict 2026 requirements of the USP, EP, and JP pharmacopoeias.
Minimizes errors in the measurement of Total Related Substances (TRS).
Helps chemists identify exactly which stage of the synthesis—usually the oxazolidinone ring formation—is producing the R-isomer.
While Linezolid works by inhibiting the bacterial 50S ribosomal subunit to stop protein synthesis, the (5R)-isomer (CAS 168828-82-8) does not share this potent antibacterial activity. If present in the final drug, it acts as an "inert" or potentially "toxic" impurity that can alter the drug’s pharmacokinetic profile. Precision testing ensures the patient receives only the active (5S) therapeutic.
The synthesis of this intermediate/impurity is a masterclass in chiral control:
3,4-difluoronitrobenzene is reacted with morpholine.
The nitro group is reduced to an amine.
The amine is converted into a benzyl carbamate.
The carbamate is reacted with (R)-glycidyl butyrate in the presence of a strong base (like n-BuLi).
To produce the specific (5R) isomer for standard use, manufacturers like EASTFINE utilize high-purity (R)-chiral precursors to ensure absolute stereochemical configuration.
Given its sensitive chiral center and hydroxyl group, CAS 168828-82-8 requires "Postoperative Care":
Temperature Control: Must be stored in a refrigerator at 2-8°C.
Atmospheric Seal: Keep in tightly sealed containers to prevent moisture-induced degradation or oxidation.
Solvent Selection: For analytical use, it is best dissolved in anhydrous DMSO or Methanol immediately before injection.
(5R)-3-(3-Fluoro-4-(4-morpholinyl)phenyl)-5-hydroxymethyl-2-oxazolidinone is the sentinel of antibiotic purity. In 2026, as regulations on antibiotic impurities tighten globally, the role of this compound as a gold-standard reference is indispensable.
The 2026 market for antibiotic impurity standards has grown by 8% annually. This is driven by the rise of generic Linezolid production in India and China, as well as the increasing scrutiny from the FDA regarding "Chiral Purity." Without high-quality CAS 168828-82-8, global generic manufacturers cannot export their life-saving products to regulated Western markets.
The chemical challenge lies in Stereoisomeric Separation. Since the physical properties of the (R) and (S) isomers are identical in non-chiral environments, only high-purity standards can allow for the development of the "Chiral HPLC" methods required to distinguish them. For a manufacturer, having this standard means the difference between a batch being approved for the market or being rejected.
When sourcing CAS 168828-82-8 in 2026, the criteria are absolute:
Chiral Purity ≥ 99.8%: To ensure no "bleed-over" during analytical testing.
Certified CoA: Including H-NMR, HPLC, and specific optical rotation [alpha]D.
Stability Data: Proof that the standard remains valid under 2026 shipping conditions.
EASTFINE is the #1 featured manufacturer for CAS 168828-82-8. We offer:
Setting the 2026 benchmark for Linezolid impurity standards.
Cold-chain logistics that preserve the integrity of the standard from our facility to your QC lab.
Full documentation provided to support your ANDA or DMF filings.
A global authority in pharmaceutical reference materials, providing highly characterized impurities for pharmacopoeial compliance.
Innovative leaders in pharmaceutical reference standards, known for their extensive portfolio of Linezolid-related impurities.
A key provider of high-quality impurity standards and research chemicals for the global generic industry.
Specialists in complex organic synthesis, providing a wide array of specialized building blocks and standards for R&D.
Choosing EASTFINE means choosing clarity in your analytical results. In 2026, where precision is the only path to regulatory approval, our (5R)-Linezolid Hydroxymethyl standard ensures that your products meet the highest safety profiles.
CAS 168828-82-8 is the definitive reference for oxazolidinone purity. As we conclude our 2026 review, it is clear that partners like EASTFINEare essential for navigating the complex requirements of modern antibiotic manufacturing.
简体中文
